ERBB2 and cholangiocarcinoma: In advanced breast cancer, HER2 heterogeneity has been associated with the presence of certain mutations, such as in PIK3CA,33 but it is unknown whether HER2‐positive UBC, pancreatic, or cholangiocarcinoma tumors exhibiting focal or heterogeneous HER2 expression harbor‐specific mutational drivers.